Condition: Alpha 1 Antitrypsin Deficiency · Sponsor: AIRNA Corporation
This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
This description comes directly from the study's public registry record.
AIRNA Corporation Clinical Trials Information · 617-609-8790 · patients@airna.com
Always discuss trial participation with your own doctor first.
| Clinical Study Center | Melbourne, Australia | Recruiting |
| Clinical Study Center 1 | Tbilisi, Georgia | Recruiting |
| Clinical Study Center 2 | Tbilisi, Georgia | Recruiting |
| Clinical Study Center | Cambridge, United Kingdom | Recruiting |
| Clinical Study Center | London, United Kingdom | Recruiting |
| Clinical Study Center | Southampton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07431112